Journal Mobile Options
Table of Contents
Vol. 222, No. 2, 2008
Issue release date: February 2008
Ophthalmologica 2008;222:117–122
(DOI:10.1159/000112629)

Transpupillary Thermotherapy in Chinese Patients with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration: Emphasis on the Influence of Power Setting

Kuo H.-K. · Kao M.-T. · Chen Y.-J. · Chen C.-H. · Wu P.-C. · Kao M.-L.
aDepartment of Ophthalmology, Chang-Gung Memorial Hospital, Kaohsiung Medical Center, Kaohsiung, and bChang-Gung University College of Medicine, Taoyuan, Taiwan

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Purpose: To perform a safety and efficacy study of transpupillary thermotherapy (TTT) in Chinese patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (ARMD). Methods: In a prospective study, patients with subfoveal or juxtafoveal CNV secondary to ARMD underwent TTT with fixed treatment and follow-up protocols. From August 2002 to December 2004, 26 patients (27 eyes) completed ≧6 months of follow-up and were included in this report. Results: Fourteen eyes (52%) had improved or stable visual acuity (loss of <3 lines) and 13 eyes (48%) had vision loss of ≧3 lines. The serial mean visual acuity initially decreased during follow-up, then stabilized by 6 months. In the subgroup of occult or minimally classic CNV (20 eyes), 13 eyes (65%) had improved or stable vision. The major complication of TTT included laser-related retinal pigment epithelium (RPE) atrophy in 10 eyes (37%). Six eyes had mild RPE atrophy, 4 eyes had severe RPE-choroid atrophy (macular burn). Analysis of possible risk factors for macular burn showed that 3 eyes had to have the power amplified due to nuclear sclerosis, and 1 pseudophakic eye had regular power. Conclusions: TTT in Chinese ARMD patients with occult or minimally classic CNV, according to our protocol, prevented severe vision loss in the majority of patients, but power amplification due to medium lens opacity induced RPE atrophy or burn in some patients.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Hyman L: Epidemiology of eye disease in the elderly. Eye 1987;1:330–341.

    External Resources

  2. Macular Photocoagulation Study Group: Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials. Arch Ophthalmol 1991;109:1109–1114.

    External Resources

  3. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials – TAP report 2. Arch Ophthalmol 2001;119:198–207.
  4. Verteporfin in Photodynamic Therapy (VIP) Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization – VIP report 2. Am J Ophthalmol 2001;131:541–560.
  5. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group: Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805–2816.
  6. The Anecortave Acetate Clinical Study Group: Anecortave acetate as monotherapy for treatment of subfoveal choroidal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology 2003;110:2372–2385.
  7. Shields CL, Shields JA, Cater J, Lois N, Edelstein C, Gunduz K, et al: Transpupillary thermotherapy for choroidal melanoma: tumor control and visual results in 100 consecutive cases. Ophthalmology 1998;105:581–590.
  8. Reichel E, Berrocal AM, Ip M, Kroll AJ, Desai V, Duker JS, et al: Transpupillary thermotherapy of occult subfoveal choroidal neovascularization in patients with age-related macular degeneration. Ophthalmology 1999;106:1908–1914.
  9. Newsom RSB, McAlister JC, Saeed M, McHugh JDA: Transpupillary thermotherapy (TTT) for the treatment of choroidal neovascularization. Br J Ophthalmol 2001;85:173–178.
  10. Thach AB, Sipperley JO, Dugel PU, Sneed SR, Park DW, Cornelius J: Large-spot size transpupillary thermotherapy for the treatment of occult choroidal neovascularization associated with age-related macular degeneration. Arch Ophthalmol 2003;121:817–820.
  11. Algvere PV, Libert C, Lindgarde G, Seregard S: Transpupillary thermotherapy of predominantly occult choroidal neovascularization in age-related macular degeneration with 12 months follow-up. Acta Ophthalmol Scand 2003;81:110–117.
  12. Gustavsson C, Agardh E: Transpupillary thermotherapy for occult subfoveal choroidal neovascularization: a 1-year, prospective randomized pilot study. Acta Ophthalmol Scand 2005;83:148–153.
  13. Rougier MB, Francois L, Fourmaux E, Isber R, Colin J, Korobelnik JF: Complications and lack of benefit after transpupillary thermotherapy for occult choroidal neovascularization: 1-year results. Retina 2005;25:784–788.
  14. Connolly BP, Regillo CD, Eagle RC, Shields CL, Shields JA, Moran H: The histopathologic effects of transpupillary thermotherapy in human eyes. Ophthalmology 2003;110:415–420.
  15. Ming Y, Algvere PV, Odergren A, Berglin L, van der Ploeg I, Seregard S, et al: Subthreshold transpupillary thermotherapy reduces experimental choroidal neovascularization in the mouse without collateral damage to the neural retina. Invest Ophthalmol Vis Sci 2004;45:1969–1974.
  16. Avery RL, Fekrat S, Hawkins BS, Bressler NM: Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. Retina 1996;16:183–189.
  17. Bressler NM, Frost LA, Bressler SB, Murphy RP, Fine SL: Natural course of poorly defined choroidal neovascularization associated with macular degeneration. Arch Ophthalmol 1988;106:1537–1542.
  18. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy and Verteporfin in Photodynamic Therapy Study Groups: Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report No 1. Am J Ophthalmol 2003;136:407–418.
  19. Chew H, Maberley DAL, Ma P, Chang A, Maberley A: Socioeconomic status and clinical features of patients undergoing photodynamic therapy or transpupillary thermotherapy for subfoveal choroidal neovascularization due to age-related macular degeneration. Can J Ophthalmol 2005;40:384–388.

    External Resources

  20. Maberley DAL, Chew H, Ma P, Chang A, Hollands H, Maberley A: Comparison of photodynamic therapy and transpupillary thermotherapy for subfoveal choroidal neovascularization due to age-related macular degeneration. Can J Ophthalmol 2005;40:378–383.

    External Resources

  21. Stolba U, Krebs I, Lamar PD, Aggermann T, Gruber D, Binder S: Long-term results after transpupillary thermotherapy in eyes with occult choroidal neovascularization associated with age-related macular degeneration: a prospective trial. Br J Ophthalmol 2006;90:158–161.
  22. Mainster MA: Decreasing retinal photocoagulation damage: principles and techniques. Semin Ophthalmol 1999;14:200–209.
  23. Mainster MA, Reichel E: Transpupillary thermotherapy for age-related macular degeneration: long-pulse photocoagulation, apoptosis, and heat shock proteins. Ophthalmic Surg Lasers 2000;31:359–373.
  24. Lanzetta P, Michieletto P, Pirracchio A, Bandello F: Early vascular changes induced by transpupillary thermotherapy of choroidal neovascularization. Ophthalmology 2002;109:1098–1104.
  25. Desmettre T, Maurage CA, Mordon S: Heat shock protein hyperexpression on chorioretinal layers after transpupillary thermotherapy. Invest Ophthalmol Vis Sci 2001;42:2976–2980.
  26. Subramanian ML, Reichel E: Current indications of transpupillary thermotherapy for the treatment of posterior segment diseases. Curr Opin Ophthalmol 2003;14:155–158.
  27. Thompson JT: Retinal pigment epithelial tear after transpupillary thermotherapy for choroidal neovascularization. Am J Ophthalmol 2001;131:662–664.
  28. Salinas-Alaman A, Garcia-Layana A, Moreno-Montanes J: Overtreatment of transpupillary thermotherapy for choroidal neovascularization. Acta Ophthalmol Scand 2003;81:197–198.
  29. Weiter JJ: Optics of laser irradiation; in Ryan SJ (ed): Retina, ed 3. St Louis, Mosby Inc, 2001, pp 499–511.
  30. Benhamou N, Cohen SY, Erginary A, Uzzan J, Brasseur G, Avni I, Gaudric A: Macular burn after transpupillary thermotherapy for occult choroidal neovascularization. Am J Ophthalmol 2004;137:1132–1135.
  31. Bloom SM, Brucker AJ: Laser Surgery of the Posterior Segment, ed 2. Philadelphia, Lippincott-Raven Publishers, 1997.
  32. Stoltz RA, Glazer-Hockstein C, Tolentino MJ, Maguire AM: Transmission of retinal laser wavelengths through blood. Retina 2005;25:498–502.
  33. Atarashi T, Tamaki Y, Inoue Y, Obata R, Muranaka K, Yanagi Y: Transpupillary thermotherapy for treatment of exudative age-related macular degeneration in Japanese patients. Eye 2004;18:615–618.
  34. Nagpal M, Nagpal K, Sharma S, Puri J, Nagpal PN: Transpupillary thermotherapy for treatment of choroidal neovascularization secondary to age-related macular degeneration in Indian eyes. Indian J Ophthalmol 2003;51:243–250.

    External Resources



Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50